High-yield points
- "CNS-PNET" no longer exists :
- Get methylation profiling on any poorly differentiated pediatric tumor.
- In ACNS0332, 71% of nonpineal "PNETs" were other tumors, mostly HGG .
- ETMR:
- Molecular: C19MC amplification or DICER1 (often germline); LIN28A-positive.
- Patients: infants.
- Outcome: 5-year OS under 30%, and brainstem cases are uniformly fatal.
- Best results: GTR plus intensive chemotherapy, with HDCT or IRS-III .
- CNS NB-FOXR2:
- Imaging: supratentorial, large, cystic and calcified, little edema.
- Outcome: 5-year OS about 85% with CSI plus chemotherapy .
- BCOR ITD:
- Patients and sites: young children; hemispheric or cerebellar.
- Outcome: chemotherapy alone fails, so radiation matters .
- Pineoblastoma is now a pineal tumor. CIC sarcoma is mesenchymal .
"CNS-PNET" was a histologic wastebasket for poorly differentiated small-round-blue-cell tumors.
- Methylation profiling broke it apart:
- Many "PNETs" were other known tumors, especially high-grade gliomas.
- The rest fell into new, molecularly defined entities with very different outcomes .
- The practical lesson:
- Get DNA methylation profiling on every poorly differentiated pediatric brain tumor.
- Treatment intensity (CSI, high-dose chemotherapy) now depends on the molecular diagnosis .
Medulloblastoma and ATRT have their own topics. Pineoblastoma is now a pineal tumor and is covered in pineal region tumors.
WHO 2021 embryonal tumors
- Medulloblastoma, molecularly and histologically defined (see Medulloblastoma) .
- Other CNS embryonal tumors :
- Atypical teratoid/rhabdoid tumor (SMARCB1, SMARCA4; see ATRT).
- Cribriform neuroepithelial tumor: a provisional entity.
- Embryonal tumor with multilayered rosettes (ETMR): C19MC or DICER1.
- CNS neuroblastoma, FOXR2-activated: FOXR2.
- CNS tumor with BCOR internal tandem duplication: BCOR. It is "not definitively neuroectodermal," since BCOR exon 15 ITDs also occur in some sarcomas.
- CNS embryonal tumor, NEC/NOS: for tumors that defy a more specific diagnosis.
- Moved out of the embryonal group :
- Pineoblastoma is now a pineal tumor.
- CIC-rearranged sarcoma is a mesenchymal tumor.
How "CNS-PNET" dissolved
- The discovery (Cell, 2016) :
- Many institutionally diagnosed CNS-PNETs had methylation profiles indistinguishable from other known entities.
- Four new entities emerged from the rest:
- CNS NB-FOXR2;
- CNS Ewing sarcoma family tumor with CIC alteration;
- HGNET-MN1 (now classified elsewhere);
- HGNET-BCOR.
- COG ACNS0332 (85 institutionally diagnosed CNS-PNET/pineoblastoma) :
- Of 31 nonpineal tumors with tissue, 71% were not PNETs:
- 18 high-grade gliomas;
- 2 ATRTs;
- 2 ependymomas.
- 5-year EFS/OS:
- true embryonal tumors and pineoblastomas: 62.8% / 78.5%;
- molecular HGG: 5.6% / 12.0%.
- Carboplatin and isotretinoin made no difference.
- International retrospective study (307 "CNS-PNETs" profiled) :
- ETMR: 19%.
- HGG: 19%.
- CNS NB-FOXR2: 12%.
- 18 other entities: 29%.
- Unclassifiable: 22%.
- Take-away: the dismal historical outcome of "PNET" was largely HGG and ETMR contamination. Molecularly true embryonal tumors do considerably better .
ETMR (embryonal tumor with multilayered rosettes)
- Who:
- Age: infants and young children. The median age was 2.9 years in the HIT cohort.
- Incidence: 1.35 per million children aged 1–4 .
- Molecular :
- Drivers:
- C19MC amplification (ETMR, C19MC-altered); or
- biallelic DICER1 mutation, usually with a germline first hit (ETMR, DICER1-altered).
- Other miRNA lesions (e.g., miR-17-92 amplification) in some.
- LIN28A is highly expressed in all ETMRs and serves as the diagnostic IHC marker .
- Genome: few recurrent point mutations but R-loop-driven chromosomal instability. Relapses carry a cisplatin-associated mutational signature .
- Location: supratentorial (hemispheric), or infratentorial including brainstem .
- Outcome, the worst of the group:
- 5-year OS:
- under 30% ;
- 24% in the international study ;
- 17.9% at St. Jude .
- P-HIT trial and registry (35 patients) :
- With carboplatin/etoposide induction plus tandem high-dose chemotherapy: 5-year PFS/OS 35%/47%.
- With other therapy: 0%/8%.
- Brainstem ETMR: all 4 died within 10 months.
- Independent favorable factors:
- supratentorial location;
- M0;
- the intensive regimen.
- IRS-III-based chemotherapy (doxorubicin, actinomycin D): 4 of 5 children after GTR were progression-free beyond 18 months. An international protocol is based on this .
- Neurosurgical points:
- GTR is part of every reported long-term survivor regimen .
- DICER1-altered ETMR: test for germline DICER1 and counsel the family .
CNS neuroblastoma, FOXR2-activated (CNS NB-FOXR2)
- The best-behaved of the group :
- International study (63 patients): 5-year PFS 63% and OS 85%. 35 of 42 progression-free survivors had received upfront CSI plus chemotherapy .
- St. Jude: 5-year EFS/OS 66.7% / 83.3% .
- A CSI-based standard-risk regimen has been proposed for prospective study .
- Imaging (25 patients, median age 4.5) :
- always supratentorial;
- large (mean 115 mL);
- little or no edema (none in 24%, limited in 60%);
- cystic or necrotic parts in 96%;
- calcification or hemorrhage in 52%;
- low ADC.
- Metastases: uncommon (20%), and nodular leptomeningeal when present.
- Clue: a big, cystic, calcified hemispheric mass in a young child with surprisingly little edema .
CNS tumor with BCOR internal tandem duplication
- Clinical and imaging (10 cases) :
- Who: young children.
- Where: cerebral or cerebellar hemispheres.
- Appearance: large, well-circumscribed, heterogeneous masses with reduced diffusion.
- Pathology:
- histology: glioma-like fibrillarity, perivascular pseudorosettes, palisading necrosis;
- IHC: strong diffuse nuclear BCOR;
- genetics: often BCOR exon 15 ITD alone .
- Outcome:
- St. Jude: chemotherapy-only regimens failed (5-year EFS 0%). Salvage radiation after progression extended survival (5-year OS 53.6%) .
- The Ferris series includes several long-term survivors .
- So radiation appears important.
The look-alikes and NEC/NOS
- Molecular HGG masquerading as PNET :
- Outcome: OS about 10–25%.
- Intensive CSI-based embryonal therapy gave no survival benefit over historical HGG regimens . Identifying them spares children unhelpful toxicity.
- CIC-rearranged sarcoma (now mesenchymal): 5-year EFS/OS 57.1%, mostly with radiation plus multidrug chemotherapy .
- CNS embryonal tumor NEC/NOS:
- When to use it: only after full molecular workup. About 22% of old "PNETs" still fit no reference class .
- Treated as one entity, old PNETs show no CSI effect:
- At St. Jude, CSI-containing and CSI-sparing therapy gave the same outcomes when "PNETs" were analyzed together.
- Differences emerged only by molecular group .
Related topics
- Medulloblastoma: the commonest embryonal tumor.
- ATRT: SMARCB1-deficient rhabdoid embryonal tumor.
- Tumors of the Pineal Region: where pineoblastoma is now covered.
- Pediatric High-Grade Glioma: the look-alike that dominated old CNS-PNET series.
References
- Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016;164(5):1060–1072. doi:10.1016/j.cell.2016.01.015. PMID 26919435. verified
- Hwang EI, Kool M, Burger PC, et al. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children's Oncology Group randomized ACNS0332 trial. J Clin Oncol 2018;36(34):JCO2017764720. doi:10.1200/JCO.2017.76.4720. PMID 30332335. verified
- von Hoff K, Haberler C, Schmitt-Hoffner F, et al. Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro Oncol 2021;23(9):1597–1611. doi:10.1093/neuonc/noab136. PMID 34077956. verified
- Liu APY, Dhanda SK, Lin T, et al. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. Acta Neuropathol 2022;144(4):733–746. doi:10.1007/s00401-022-02484-7. PMID 35982322. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Juhnke BO, Gessi M, Gerber NU, et al. Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. Neuro Oncol 2022;24(1):127–137. doi:10.1093/neuonc/noab100. PMID 33908610. verified
- Lambo S, Gröbner SN, Rausch T, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature 2019;576(7786):274–280. doi:10.1038/s41586-019-1815-x. PMID 31802000. verified
- Lambo S, von Hoff K, Korshunov A, Pfister SM, Kool M. ETMR: a tumor entity in its infancy. Acta Neuropathol 2020;140(3):249–266. doi:10.1007/s00401-020-02182-2. PMID 32601913. verified
- Hanson D, Hoffman LM, Nagabushan S, et al. A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes. Neurooncol Adv 2020;2(1):vdaa120. doi:10.1093/noajnl/vdaa120. PMID 33196040. verified
- Tietze A, Mankad K, Lequin MH, et al. Imaging characteristics of CNS neuroblastoma-FOXR2: a retrospective and multi-institutional description of 25 cases. AJNR Am J Neuroradiol 2022;43(10):1476–1480. doi:10.3174/ajnr.A7644. PMID 36137662. verified
- Ferris SP, Velazquez Vega J, Aboian M, et al. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication—a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathol 2020;30(1):46–62. doi:10.1111/bpa.12747. PMID 31104347. verified
Verification (2026-11-13):
- Each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed.
- Numbers were checked against the PubMed abstracts.
- The WHO 2021 lists of entities and genes come from the full text of reference 5 (Tables 1–2), read via a fetch of PMC8328013.
Caveats:
- The "small-round-blue-cell wastebasket" framing and the family-counseling advice are standard teaching.
- All outcome data are retrospective or registry-based, with small numbers per entity.
- The figure is an original schematic.